Curcumin Inhibits Transforming Growth Factor-beta 1-Induced EMT via PPAR gamma Pathway, Not Smad Pathway in Renal Tubular Epithelial Cells

Rui Li, Fudan University
Yunman Wang, Shanghai University of Traditional Chinese Medicine
Yujun Liu, Shanghai University of Traditional Chinese Medicine
Qijing Chen, Fudan University
Wencheng Fu, Shanghai University of Traditional Chinese Medicine
Hao Wang, Shanghai University of Traditional Chinese Medicine
Hui Cai, Emory University
Wen Peng, Shanghai University of Traditional Chinese Medicine
Xuemei Zhang, Fudan University

Journal Title: PLoS ONE
Volume: Volume 8, Number 3
Publisher: Public Library of Science | 2013-03-27, Pages e58848-e58848
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1371/journal.pone.0058848
Permanent URL: https://pid.emory.edu/ark:/25593/rxbn8

Final published version: http://dx.doi.org/10.1371/journal.pone.0058848

Copyright information:
© 2013 Li et al.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed December 12, 2023 3:09 AM EST
Curcumin Inhibits Transforming Growth Factor-β1-Induced EMT via PPARγ Pathway, Not Smad Pathway in Renal Tubular Epithelial Cells

Rui Li1,*, Yunman Wang2,*, Yujun Liu2, Qijing Chen1, Wencheng Fu2, Hao Wang3, Hui Cai3,4, Wen Peng2,*, Xuemei Zhang1*

1 Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China, 2Department of Nephrology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 3Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America, 4Renal Section, Atlanta Veteran Administration Medical Center, Decatur, Georgia, United States of America

Abstract

Tubulointerstitial fibrosis (TIF) is the final common pathway in the end-stage renal disease. Epithelial-to-mesenchymal transition (EMT) is considered a major contributor to the TIF by increasing the number of myofibroblasts. Curcumin, a polyphenolic compound derived from rhizomes of Curcuma, has been shown to possess potent anti-fibrotic properties but the mechanism remains elusive. We found that curcumin inhibited the EMT as assessed by reduced expression of α-SMA and PAI-1, and increased E-cadherin in TGF-β1 treated proximal tubular epithelial cell HK-2 cells. Both of the conventional TGF-β1/Smad pathway and non-Smad pathway were investigated. Curcumin reduced TGF-β1 receptor type I (TβRI) and TGF-β receptor type II (TβRII), but had no effect on phosphorylation of Smad2 and Smad3. On the other hand, in non-Smad pathway curcumin reduced TGF-β1-induced ERK phosphorylation and PPARγ phosphorylation, and promoted nuclear translocation of PPARγ. Further, the effect of curcumin on α-SMA, PAI-1, E-cadherin, TβRI and TβRII were reversed by ERK inhibitor U0126 or PPARγ inhibitor BADGE, or PPARγ shRNA. Blocking PPARγ signaling pathway by inhibitor BADGE or shRNA had no effect on the phosphorylation of ERK whereas the suppression of ERK signaling pathway inhibited the phosphorylation of PPARγ. We conclude that curcumin counteracted TGF-β1-induced EMT in renal tubular epithelial cells via ERK-dependent and then PPARγ-dependent pathway.

Introduction

Renal fibrosis, characterized by accumulation of fibroblasts and excessive matrix proteins along with loss of functioning nephrons, is a major pathological feature of progressive kidney disease. Tubulointerstitial fibrosis is considered the final common pathway of renal fibrosis. Recent studies have demonstrated that a critical step in the pathogenesis of tubulointerstitial fibrosis is epithelial-mesenchymal transition (EMT) [1], a process whereby fully differentiated epithelial cells undergo transition to a mesenchymal phenotype. EMT causes a substantial increase in the number of myofibroblasts, one of main effectors cells that contributes to the development of progressive renal fibrosis [2].

TGF-β is known as a major inducer of EMT. TGF-β1 induced EMT via Smad-dependent and Smad-independent pathways [3]. Through the Smad mediated pathway, TGF-β signals are transduced by transmembrane serine/threonine kinase type II and type I receptors (TβRII and TβRI) and intracellular mediators Smads [4]. In the non-Smad signaling pathway, TGF-β receptors interact with the MAPK pathway [5]. There are also reports that Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation exerts antiproliferative and antifibrotic effects via the modulation of TGF-β1-mediated pathways [6].

PPAR-γ is a member of the nuclear receptor family of transcription factors. Ligands for PPAR-γ include a variety of natural and synthetic compounds. Synthetic ligands are often used as insulin sensitizing agents for treatment of type 2 diabetes [7]. Studies have demonstrated that PPARγ agonists exert protective effects in the models of renal diseases [8,9]. PPARγ agonists rosiglitazone significantly attenuated glomerulosclerosis, tubulointerstitial expansion and collagen IV deposition in the apolipoprotein E knock out mouse [10]. Troglatizone, another PPARγ agonists, also attenuated renal interstitial fibrosis and inflammation in the unilateral ureteral obstruction’s animal (UUO) [11], a classic renal fibrosis model.

Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadience-3,5-dione] is a natural polyphenolic compound derived from the root of curcuma longa that has been widely used in India for medical, culinary and other purposes. A large body of evidence from in vitro and in vivo studies of both animals and human have
indicated that curcumin exhibits a variety of biological effects such as anti-oxidant, anti-inflammatory, anti-tumor and wound healing properties [12]. In particular, some recent studies have shown that curcumin has anti-fibrotic effect in liver, lung and cystic fibrosis [13,14,15]. In UUO rat kidney fibrosis model curcumin has been reported to inhibit the renal interstitial inflammation and fibrosis by inhibiting of the NF-κB-dependent pathway [16]. In immortalized rat kidney interstitial fibroblasts (NRK/49F), curcumin attenuated TGF-β-induced fibrosis through down-regulation of TβR II [17].

Curcumin has been reported to activate PPAR-γ as well [18], but it is unclear the effect is depend on binding to the receptor of PPAR-γ [18] or is the result of indirect effects [19]. Thus, we hypothesized that curcumin may inhibit renal fibrosis as assessed by EMT through PPARγ pathways in the TGF-β signaling. On the other hand, researches on the anti-renal fibrosis effect of curcumin have been concentrated on the mediating role of Smad pathway and little is known about curcumin’s effects through the non-Smad pathway such as MAPK, and whether there is any cross talk between MAPK and PPARγ is still elusive. Here, we reported the effect of curcumin on TGF-β1-induced EMT in renal tubular epithelial cells, and its underlying mechanisms related to non-Smad ERK1/2 and PPARγ pathways.

**Materials and Methods**

**Cell culture and treatment**

Human proximal tubular epithelial cells (HK-2 cells) were cultured in RPMI 1640 containing 2000 mg/L NaHCO3, supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin in an atmosphere of 5% carbon dioxide and 95% air at 37°C. Normal Rat Kidney (NRK-52E) proximal
cells were cultured in DMEM containing 2000 mg/L NaHCO₃, supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin in an atmosphere of 5% carbon dioxide and 95% air at 37°C.

At about 90% confluent, the cells were trypsinized by treatment with trypsin-EDTA and seeded in 6-well plates, grown to confluence, and rested in medium without FBS overnight.

Reagents
Curcumin [1,7-bis(4-hydroxy-3methoxyphenyl)-1,6-heptadiene-3,5-dione] was purchased from Sigma (St. Louis, MO, USA). Stock solutions of curcumin were prepared in dimethyl sulfoxide and used at a final concentration ≤0.1% (v/v). Recombinant Human transforming growth factor beta 1 (TGF-β1) were purchased from R&D Systems (USA). Antibodies to phospho-smad2, smad2, phospho-smad3, smad3, phospho-ERK1/2, ERK 1/2, PPARγ and TGF-β receptor II were purchased from Cell Signaling Technology (USA). Antibodies to p-PPARγ were purchased from Bioworld (USA). TGF-β receptor I was purchased from Santa Cruz Biotechnology (CA, USA). Antibodies to PAI-1, E-cadherin and α-SMA were purchased from Epitomics (USA). BCA Protein Assay Kit was purchased from Shanghai Biocolor BioScience & Technology Company (China).

Western blot analysis
At the time of harvest, cells were washed twice with PBS (135 mM, 2.7 mM KCl, 1.5 mM KH₂PO₄, 8 mM K₂HPO₄), homogenized in RIPA lysis buffer (150 mM NaCl, 1% Triton X-100, 0.1% SDS, 50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM PMSF). The supernatants were collected after centrifugation at 10,000×g at 4°C for 15 min. Protein concentration was determined using a BCA Protein Assay Kit. Equal amounts of protein were boiled at 95°C for 5 min after the addition of 5× Laemmli buffer. Protein samples were separated by 10% SDS gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes. After blocking with 5% dry milk in Tris-buffered saline with 0.1% Tween (TBST) at room temperature for 2 h, the membranes were incubated with primary antibodies at 4°C overnight. After being washed in TBST three times, the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody at room temperature for 1 h. The signals were visualized using the enhanced chemiluminescent (ECL) substrate.

Stable shRNA mediated repression of PPARγ in HK-2 cells
Human PPARγ expression in HK-2 cells was silenced by shRNA interference. The lentiviral mediated shRNA against PPARγ (NM_138712.3) system was purchased from Shanghai Sunbio Medical Biotechnology. An adopted non-silencing control shRNA sequence (TTCTCCGAACGTGTCACGT) that was not complementary to any human gene was used as a control shRNA. Lentiviruses were prepared in HEK293T cells followed by infecting HK-2 cells. Cells were selected using 0.5 μg/ml puromycin and subjected to western blot to test the expression level of PPARγ in the infected HK-2 cells.

Immunofluorescent staining and fluorescent microscopy
HK-2 cells grown on cover slips were washed with cold PBS three times and fixed in 5% paraformaldehyde for 25 minutes. The cells were then extensively washed three times each for 10 minutes with PBS and permeabilized with 0.1% TritonX-100 for 5 minutes. After blocking in 5% bovine serum albumin (BSA)
in PBS buffer for 1 hour at room temperature, cells were incubated with the anti-PPARγ antibody at 4°C overnight with gentle rocking. Cells were next washed three times in PBS and stained with Cy-2-conjugated secondary antibody at room temperature for 2 hours. Stained cells were mounted with antifade mounting medium on slides and viewed with a fluorescence microscope.

Statistical Analysis

The data are shown as mean±SD. Statistical significance was assessed using a Student’s paired t test when there were only two groups involved. P<0.05 was considered statistically significant. All data analyses were performed using the SPSS software.

Results

1. Curcumin inhibited the expression of α-SMA and PAI-1 and increased E-cadherin in TGF-β1 treated HK-2 cells

As shown in Fig. 1, the amount of α-SMA and PAI-1 proteins were very low while the epithelial cell marker, E-cadherin was prominent in normal HK-2 cells (Fig. 1 b). TGF-β1 induced a significant increase in α-SMA and PAI-1 and decrease in E-cadherin (Fig. 1 b & c). Curcumin down-regulated α-SMA and PAI-1 and up-regulated E-cadherin (Fig. 1 b & c).

Figure 4. Effects of curcumin on TGF-β1-induced ERK phosphorylation in HK-2 cells. (A) HK-2 cells were stimulated with TGF-β1 (2.5 ng/ml) for the indicated times, and the phosphorylation of ERK was analyzed by western blotting. (B) Western blotting analyses for p-ERK expression in HK-2 cells. HK-2 cells were incubated with curcumin at the indicated doses for 12 hours followed by treatment with TGF-β1 for 30 minutes. (C) Graphical presentation of the relative expression of pERK. The values were represented as the density of p-ERK vs total ERK (%). The mean ± SD (n = 3) of values were obtained from densitometric analysis of all individual experiments. *P<0.05 vs. control alone, #P<0.05 vs TGF-β1 alone.

doi:10.1371/journal.pone.0058848.g004

2. Curcumin attenuated the TGF-β1-induced expression of TGF-β receptor type I (TβRI) and TGF-β receptor type II (TβRII) in HK-2 cells

Binding to the TGF-β receptor type II (TβRII) is the first step of TGF-β1 signaling, and the TβRII in turn phosphorylates TGF-β receptor type I (TβRI) [20]. To determine whether the anti EMT effect of curcumin is targeting TGF-β1-related signaling, we

Figure 5. Curcumin reduced TGF-β1-induced PPARγ phosphorylation and reversed the reduction of PPARγ. HK-2 cells were incubated with curcumin at the indicated dose for 12 hours or rosiglitazone for 1 hour followed by treatment with TGF-β1 for 36 hours. (A) Western blotting analyses for PPARγ and p-PPARγ expression in HK-2 cells. (B) Graphical presentation of the relative expression of PPARγ and p-PPARγ. The values were represented as the density of PPARγ and p-PPARγ vs β-actin (%). The mean ± SD (n = 3) of values were obtained from densitometric analysis of all individual experiments. *P<0.05 vs control alone, *P<0.05 vs TGF-β1 alone.

doi:10.1371/journal.pone.0058848.g005

Figure 6. Effects of curcumin on nuclear translocation of PPARγ. HK-2 cells were pretreated with curcumin (10 μM) for 12 hours (C) or rosiglitazone (10 μM) for 1 hour (D) following by incubated with TGF-β1 for 36 hours. Red for PPARγ.

Figure 7. Curcumin reduced TGF-β1-induced expression of PPARγ in HK-2 cells. (A) Immunofluorescence analyses for PPARγ expression in HK-2 cells. HK-2 cells were incubated with curcumin at the indicated dose for 12 hours or rosiglitazone for 1 hour followed by treatment with TGF-β1 for 36 hours. (B) Immunofluorescence analyses for PPARγ expression in HK-2 cells. HK-2 cells were incubated with curcumin at the indicated dose for 12 hours or rosiglitazone for 1 hour followed by treatment with TGF-β1 for 36 hours. Red for PPARγ.

Figure 8. Effects of curcumin on nuclear translocation of PPARγ. HK-2 cells were pretreated with curcumin (10 μM) for 12 hours (C) or rosiglitazone (10 μM) for 1 hour (D) following by incubated with TGF-β1 for 36 hours. Red for PPARγ.
studied the effects of curcumin on TβR II and TβR I. As shown in Fig. 2, curcumin decreased both TβRI and TβR II expression in HK-2 cells.

3. Effects of curcumin on TGF-β1-induced Smad2 and Smad3 phosphorylation in HK-2 cells

We then studied the effects of curcumin on Smad2 and Smad3, two important mediators of the TGF-β/Smads signaling, which has been known to play a major role in TGF-β1-induced EMT [21].

Smad2 and Smad3 were phosphorylated at 5 min and the phosphorylations reached the peak levels at 30 min (Fig. 3a). Pretreatment with curcumin for 12 hours and following by treatment with TGF-β1 for 30 minutes has no effect on phosphorylation of Smad2 and Smad3 (Fig. 3b). These data indicated that the inhibition of TGF-β1-induced EMT by curcumin is not through TGF-β1/Smads signaling pathway.

4. Curcumin reduced TGF-β1-induced ERK phosphorylation in HK-2 cells

Our studies showed that curcumin had little effect on TGF-β/Smads signaling. Since the activation of TβRI and TβR II can lead to the activation of other EMT associated signaling pathways, such as ERK [22], we examined the influence of curcumin on ERK signaling. ERK was phosphorylated at 5 min and reached the peak levels at 30 min post TGF-β1 treatment (Fig. 4a). Pretreatment with curcumin for 12 hours and following by treatment with TGF-β1 for 30 minutes decreased phosphorylation of ERK (Fig. 4b). These data indicated that curcumin may inhibit TGF-β1-induced EMT through ERK-related signaling pathway.

5. Curcumin reduced TGF-β1-induced PPARγ phosphorylation and promoted nuclear translocation of PPARγ

Total PPARγ expression was reduced while its phosphorylation was increased after being treated with TGF-β1 (Fig. 5). Pretreatment with curcumin for 12 hours increased PPARγ expression level and inhibited the phosphorylation of PPARγ. As expected, PPARγ agonist rosiglitazone increased PPARγ expression. We also found that rosiglitazone inhibited the phosphorylation of PPARγ. These results indicated that curcumin is a PPARγ agonist.

PPARγ is a nuclear transcription factor, which requires nuclear translocation. As shown in Fig. 6, TGF-β1 decreased the expression of PPARγ, and curcumin increased the expression of PPARγ and promoted nuclear translocation of PPARγ in HK-2 cells. Rosiglitazone also promoted nuclear translocation of PPARγ.

Figure 7. ERK1/2 inhibitor U0126 and PPARγ inhibitor BADGE blocked the effects of curcumin on TGF-β1-induced EMT in HK-2 cells.

(A) Effects of U0126, BADGE on the expression of α-SMA, PAI-1, E-cadherin, TβR I and TβR II with or without TGF-β1. HK-2 cells were pretreated with curcumin (10 μM) for 12 hours followed by treatment with U0126 (10 μM) or BADGE (10 μM) for 36 hours or HK-2 cells were pretreated with U0126 (10 μM) or BADGE (10 μM) for 1 hour before addition of TGF-β1 (2.5 ng/ml) for 36 hours. (B) Effects of curcumin on the expression of α-SMA, PAI-1, E-cadherin, TβR I and TβR II with TGF-β1 and U0126 or BADGE. HK-2 cells were pretreated with curcumin (10 μM) for 12 hours at indicated dose followed by treatment with U0126 (10 μM) or BADGE (10 μM) for 1 hour before addition of TGF-β1 (2.5 ng/ml) for 36 hours. doi:10.1371/journal.pone.0058848.g007
6. ERK pharmacological inhibitor and PPARγ pharmacological inhibitor blocked the inhibitory effect of curcumin on TGF-β1-induced EMT of HK-2 cells

To elucidate whether the inhibition of ERK and PPARγ signaling are necessary for the effect of curcumin on TGF-β1-induced EMT of HK-2 cells, we pretreated HK-2 cells with U0126, a pharmacological inhibitor of ERK, or BADGE, a pharmacological inhibitor of PPARγ. In order to exclude the influence of curcumin or inhibitors on the protein expression, we have designed a control experiment with or without TGF-β1. As shown in Fig. 7a, in the absence of TGF-β1, curcumin, U0126, BADGE and curcumin combined with U0126, or BADGE did not have any effect on the protein levels of α-SMA, E-cadherin, TβRI and TβRII, and there was no significant difference compared with the control group. Similarly, in the presence of TGF-β1, U0126 or BADGE did not have any effect on establishment of model, and there was no significant difference compared with TGF-β1 treated group. Based on the above results, we studied the effects of curcumin with U0126 or BADGE on α-SMA, E-cadherin, PAI-1, TβRI and TβRII. The U0126 or BADGE treatment was shown to reverse the increases in α-SMA, PAI-1, TβRI and TβRII and the decreases in E-cadherin caused by curcumin (Fig. 7b).

7. Effect of curcumin on TGF-β1-induced EMT in HK-2 cells is dependent on PPARγ

Furthermore, we knocked down the expression of PPARγ at cellular level using shRNA interference via lentiviral infection of HK-2 cells. Results from western blotting showed that the PPARγ protein in knocked-down cells was significantly lower compared to that in normal cells and scrambled shRNA infected cells (Fig. 8b). With the significantly decreased PPARγ expression by shRNA the effects of curcumin on α-SMA, PAI-1, E-cadherin, TβRI and TβRII were inhibited (Fig. 8b).

8. ERK phosphorylates PPARγ in HK-2 cells

Blocking PPARγ signaling pathway by inhibitor BADGE or shRNA (Fig. 9a & 9b) had no effect on the phosphorylation of PPARγ. Blocking PPARγ signaling pathway by inhibitor BADGE or shRNA in HK-2 cells had no effect on the phosphorylation of PPARγ.

Figure 8. Effect of curcumin on TGF-β1-induced EMT in HK-2 cells is dependent on PPARγ. (A) Knockdown of PPARγ in HK-2 cells. HK-2 cells were infected with PPARγ-specific shRNA or scrambled shRNA for 3 hours and then changed the medium. The expression of PPARγ was examined by western blotting. (B) After infected with PPARγ-specific shRNA or scrambled shRNA for 3 hours, HK-2 cells were treated with curcumin (10 μM) for 12 hours at indicated dose followed by treatment with TGF-β1 (2.5 ng/ml) for 36 hours. Expression of α-SMA, PAI-1, E-cadherin, TβRI and TβRII were detected by western blotting.

doi:10.1371/journal.pone.0058848.g008

Figure 9. Crosstalk between ERK and PPARγ signaling. (A) Effect of blocking PPARγ signaling by pharmacological inhibitor on phosphorylation of ERK. HK-2 cells were pretreated with BADGE (10 μM) 1 hour before addition of TGF-β1 (2.5 ng/ml) for 30 minutes and the expression of p-ERK were analyzed by western blotting. (B) Effect of knockdown of PPARγ at cellular level on phosphorylation of ERK. HK-2 cells infected with PPARγ-specific shRNA or scrambled shRNA were treated TGF-β1 (2.5 ng/ml) for 30 minutes and the expression of p-ERK were analyzed by western blotting. (C) Effect of blocking ERK signaling on phosphorylation of PPARγ. HK-2 cells were pretreated with U0126 (10 μM) for 1 hour before addition of TGF-β1 (2.5 ng/ml) for 36 hours and the expression of PPARγ were analyzed by western blotting.

doi:10.1371/journal.pone.0058848.g009

Figure 10. Effects of curcumin on TGF-β1-induced EMT in NRK-52E cells. NRK-52E cells were incubated with curcumin at the indicated dose for 12 hours followed by treatment with TGF-β1 (2.5 ng/ml) or 30 min(P-Smad2 and P-Smad3). (A) Western blotting analysis for PAI-1 expression. (B) Western blotting analysis for P-Smad2 and P-Smad3 expression. (C) Western blotting analysis for PPARγ and p-PPARγ expression.

doi:10.1371/journal.pone.0058848.g010
ERK whereas the suppression of ERK signaling pathway inhibited the phosphorylation of PPARγ (Fig. 9c). These data suggest that ERK signaling pathway is the upstream of PPARγ signaling pathway in the regulation of EMT in HK-2 cells.

9. Effect of curcumin on TGF-β1-induced EMT in NRK-52E cells

Curcumin is also able to block TGF-β1-induced EMT in NRK-52E cells, another renal tubular epithelial cell line (Fig. 10a). As shown in Fig. 10b & 10c, curcumin had no effect on p-Smad2 and p-Smad3, whereas reduced TGF-β1-induced PPARγ phosphorylation and increased the expression of total PPARγ, which is similar to the effects of curcumin on HK-2 cells.

Discussion

In this study, we investigated the effect of curcumin on TGF-β1-induced EMT in HK-2 cells and the underlying mechanism. Increased expression of α-cadherin and PAI-1 and decreased expression of E-cadherin are the hallmarks of renal tubular epithelial cells undergoing EMT [1,23,24]. Suppression of E-cadherin is considered the earliest changes in TGF-β1-induced EMT [25]. A-SMA is an important marker of fibroblast, contributing to the morphology of the transferred cells and to their ability to migrate and invade. PAI-1, a potent inhibitor of uPA/PA (urokinase/tissue-type plasminogen activators), plays a major role in extracellular matrix (ECM) accumulation and degradation [26], which is a principal feature in fibrosis. In this study, we observed that with pretreatment of curcumin, the increase of α-cadherin and PAI-1 induced by TGF-β1 was attenuated, and the loss of E-cadherin was reversed, confirming the previous reports [17,27]. These results indicated that curcumin inhibits the process of EMT in renal tubular cell lines.

The mechanisms underlying the effect of curcumin on EMT of HK-2 cells were further investigated. Since binding of TGF-β1 to TβRI and TβRII is the first step of TGF-β signaling [28], we first examined the effect of curcumin on the levels of TβRI and TβRII. Our studies showed that curcumin could inhibit the expression of both TβRI and TβRII, but Gaedke et al found that curcumin selectively inhibited TβRII in renal fibroblasts cells. It suggested that the signaling might be differ in tubular and fibroblasts cells.

TGF-β/Smads signaling is considered the most important pathway in EMT and most of the TGF-β-induced EMT appears to be dependent on this signaling. The phosphorylation of Smad2 and Smad3 are essential steps in the signaling cascade. Curcumin was previously demonstrated to suppress the phosphorylation of Smad2 but not that of Smad3 in HK-2 cells [27]. Li et al reported that curcumin inhibited the phosphorylations of both Smad2 and Smad3 in UUO rat model [29]. However, in our study, curcumin failed to affect the phosphorylations of both Smad2 and Smad3 in HK-2 cells and NRK-52E cells. The different findings of the phosphorylations of Smad2 and Smad3 by curcumin treatment may be cell type specific, suggesting that the phosphorylation status and effect of Smad2 and Smad3 in EMT are complex and involve many factors.

Besides TGF-β/Smads pathway, TGF-β receptors activate some non-Smad signaling pathways as well, including ERK pathway et al. Studies have demonstrated that ERK is phosphorylated during TGF-β1-induced EMT [30], ERK activity is required for disassembly of adherens junctions and induction of cell motility, and blockade of ERK inhibited key morphological features of EMT in the mammary gland epithelial cells [31], hence the inhibition of phosphorylation of ERK is a potential target for suppressing renal fibrosis. In our study in HK-2 cells, ERK phosphorylation was detected at 5 min after treating with TGF-β1, whereas curcumin attenuated the TGF-β1-induced increase of p-ERK. We pretreated HK-2 cells with U0126, a pharmacological inhibitor of ERK, the inhibitory effect of curcumin on EMT was reduced, indicating that the inhibitory effect of curcumin on EMT is related to its inhibition on ERK signaling.

PPARγ is present and active in multiple renal cell type including the cultured glomerular mesangial cells, podocytes, proximal epithelial cells and epithelial cells of collecting ducts [32,33]. Studies have shown that PPARγ agonists could ameliorate renal fibrotic lesions in diabetic nephropathy and nondiabetic chronic kidney diseases [34,35,36]. In this study, we demonstrated, for the first time, that curcumin induces the expression of PPARγ, inhibits the phosphorylation of PPARγ and promotes the nuclear translocation of PPARγ in renal tubular epithelial cells. Curcumin has been reported to activate PPARγ, but whether it is a ligand is still a debate [19]. The mechanisms by which curcumin induces PPARγ expression remain poorly understood. Two possibilities may be involved: firstly, curcumin binds to its own receptor and the complex stimulates the PPARγ signaling pathway resulting in the up-regulation of PPARγ [19]; secondly, curcumin is a ligand of PPARγ, and binds directly to PPARγ, leading to the activation of PPARγ [18]. Activation of PPARγ by curcumin is important for the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin. Down-regulation of PPARγ by its pharmacology inhibitor BADGE or shRNA significantly weakened the inhibition of EMT by curcumin.

In conclusion, our studies, for the first time, provided evidence for a protective role of curcumin in counteracting TGF-β1-induced EMT in renal tubular epithelial cells via ERK-dependent and then PPARγ-dependent pathway.

Author Contributions

Modified the draft: XMZ HC. Conceived and designed the experiments: XMZ WP. Performed the experiments: RL YMW. Analyzed the data: RL YJL. Contributed reagents/materials/analysis tools: WCF HW QJC. Wrote the paper: RL.
Curcumin Inhibits EMT via PPARγ Pathway

2. Yang J, Liu Y (2001) Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. The American Journal of Pathology 159: 1465–1475.

3. Derynick R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577–584.

4. Miyazono K, Tan Dijie P, Heldin CH (2000) TGF-β signaling by Smad proteins. Advances in immunology 75: 113–157.

5. Moustakas A, Heldin CH (2005) Non-Smad TGF-β signals. Journal of Cell Science 118: 3373–3384.

6. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, et al. (2008) PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β. Laboratory Investigation 89: 47–58.

7. Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annual review of medicine 53: 409–435.

8. Yang J, Zhang D, Li J, Zhang X, Fan F, et al. (2009) Role of PPARγ in repersistence in Type 2 diabetes: molecular mechanisms and therapeutic potential. Clinical Science 116: 17.

9. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB (2001) Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against non-diabetic glomerulosclerosis in rats. Kidney International 59: 1899–1910.

10. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Massue K, et al. (2002) Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Molecular and Cellular Biology 22: 2607–2619.

11. Han JY, Kim YJ, Kim I, Choi SJ, Park IS, et al. (2010) PPARγ Agonist and Angiogenesis II Receptor Antagonism Ameliorate Renal Tubulointerstitial Fibrosis. Journal of Korean medical science 25: 35.

12. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC (2006) Multiple biological activities of curcumin: a short review. Life Sciences 78: 2081–2087.

13. Kuwabara N, Tamada S, Iwai T, Teramoto K, Kaneda N, et al. (2006) Attenuation of renal fibrosis by curcumin in rats. BMC Complementary and Alternative Medicine 12: 136.

14. Pann汕vathai D, Venkatesan N, Babu M (2009) Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British Journal of Pharmacology 151:169–172.

15. Lipecka J, Norcz C, Benouaen N, Baudouin-Legros M, Planelles G, et al. (2006) Rescue of A549 CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) by Curcumin: Involvement of the Keratin 18 Network. Journal of Pharmacology and Experimental Therapeutics 317: 500–505.

16. Kuwabara N, Tamada S, Iwai T, Terramoto K, Kaneda N, et al. (2006) Attenuation of renal fibrosis by curcumin in rat obstructive nephropathy. Urology 67: 440–446.

17. Gaeckle J, Noble NA, Border WA (2004) Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells. Kidney International 66: 112–120.

18. Chen A, Xu J (2005) Activation of PPARγ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. American Journal of Physiology-Gastrointestinal and Liver Physiology 289: G447–G456.

19. Narala VR, Smith MR, Adapala RK, Ranga R, Panati K, et al. (2009) Curcumin is not a ligand for peroxisome proliferator-activated receptor-gamma. Gene Ther Mol Biol 13: 20–25.

20. Wu MY, Hill CS (2009) TGF-β Superfamily Signalling in Embryonic Development and Homeostasis. Developmental Cell 16: 329–343.

21. Wang W, Koka V, Lau HV (2005) Transforming growth factor-β and Smad signalling in kidney diseases. Nephrology 10: 48–56.

22. Yan X, Liu Z, Chen Y (2009) Regulation of TGF-β signaling by Smad7. Acta Biochimica et Biophysica Sinica 41: 263–272.

23. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. Journal of Clinical Investigation 112: 1776–1784.

24. Zavadil J, Boninger EP (2005) TGF-β and epithelial-to-mesenchymal transitions. Oncogene 24: 5764–5774.

25. Willis BC, Borek Z (2007) TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. American Journal of Physiology-Lung Cellular and Molecular Physiology 293: L525–L534.

26. Ghosh AK, Vaughan DE (2012) PAI-1 in tissue fibrosis. Journal of Cellular Physiology 227: 493–507.

27. Hu Y, Liang H, Du Y, Zhu Y, Wang X (2010) Curcumin Inhibits Transforming Growth Factor-β Activity via Inhibition of Smad Signaling in HK-2 Cells. American Journal of Nephrology 31: 332–341.

28. Rojas A, Padidam M, Cress D, Grady WM (2009) TGF-[beta] receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-[beta]. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1793: 1165–1173.

29. Li Y, Chen Z, Li Y (2011) Effects of curcumin on the epithelial mesenchymal transition and TGF-beta/Smads signaling pathway in unilateral ureteral obstruction rats. Zhongguo Zheng yu Jian yan zhu ban 31: 1224.

30. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, et al. (2004) Activation of the Erk pathway is required for TGF-β1-induced EMT in vitro. Neoplasia (New York, NY) 6: 603.

31. Xie L, Law BK, Aakre ME, Edgerton M, Shyr Y, et al. (2003) Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res 5: R187–R198.

32. Abbott BD (2009) Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development. Reproductive Toxicology 27: 246–257.

33. Kiss-Toth E, Rösser T (2008) PPARs in Kidney Physiology and Pathophysiology. PPAR Research 2008: 183108.

34. Panchapakesan U, Sumual S, Pollock CA, Chen X (2005) PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. American Journal of Physiology-Renal Physiology 289: F1153–F1158.

35. Ko, GJ, Kong YS, Han SY, Lee MH, Song HK, et al. (2008) Poglistatone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrology Dialysis Transplantation 23: 2750–2760.

36. Chung B, Lim S, Ahn K, Sugawara A, Ko I, et al. (2005) Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases. Nephrology 10: 840–843.

37. Chen A, Zheng S (2009) Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF-κB and ERK signalling. British Journal of Pharmacology 153: 557–567.

38. Ghosh SS, Massey HD, Krieg R, Fazelhoya ZA, Ghosh S, et al. (2009) Curcumin ameliorates renal ailure in 5/6 nephrectomized rats: role of inflammation. American Journal of Physiology-Renal Physiology 296: F1146–F1157.

39. Gao J, Zhou H, Lei T, Zhou L, Li W, et al. (2011) Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. European journal of pharmacology 654: 92–99.

40. Dziradzovian C, Gizard J, Péroniez JP (2005) Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87: 33–38.

41. Rochette-Egly C (2003) Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cellular Signalling 15: 355–366.

42. Burgermeister E, Seger R (2008) PPARγ and MIEK Interactions in Cancer. PPAR Research 2008: 1–16.